Patents Assigned to Array Biopharma Inc.
  • Pyrazole [3, 4-B] pyridine Raf inhibitors
    Patent number: 8394795
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 12, 2013
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: Kateri A. Ahrendt, Alexandre J. Buckmelter, Jason De Meese, Jonas Grina, Joshua D. Hansen, Ellen R. Laird, Paul Lunghofer, David Moreno, Brad Newhouse, Li Ren, Jeongbeob Seo, Hongqi Tian, Steven Mark Wenglowsky, Bainian Feng, Janet Gunzner, Kim Malesky, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Wendy B. Young
  • Process for preparing benzimidazole compounds
    Patent number: 8383832
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ib-1: wherein Z, X1, X2, X5, R2b and R10 are as defined herein. Compounds of Formula Ib-1 can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: February 26, 2013
    Assignees: Array BioPharma Inc., AstraZeneca AB
    Inventors: John Demattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
    Patent number: 8377937
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: February 19, 2013
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith L. Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Jun Liang, Brian S. Safina
  • Pyrazolopyridines as kinase inhibitors
    Patent number: 8372842
    Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: February 12, 2013
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Indrani W. Gunawardana, Yvan Le Huerou, Peter J. Mohr, Eli M. Wallace, Bin Wang
  • 2-aminopyridine analogs as glucokinase activators
    Patent number: 8362037
    Abstract: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: January 29, 2013
    Assignee: Array BioPharma, Inc.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Ronald Jay Hinklin, Ajay Singh
  • 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
    Patent number: 8362056
    Abstract: Compounds of Formula I: I in which D1, D2, R1, R2, R7, R8 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    Type: Grant
    Filed: November 4, 2008
    Date of Patent: January 29, 2013
    Assignee: Array BioPharma Inc.
    Inventor: George A. Doherty
  • 2-aminopyridine analogs as glucokinase activators
    Patent number: 8354540
    Abstract: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: January 15, 2013
    Assignee: Array BioPharma Inc.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Ronald Jay Hinklin, Ajay Singh
  • DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20120329808
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: July 5, 2007
    Publication date: December 27, 2012
    Applicant: Array Biopharma Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik
  • Raf inhibitor compounds and methods of use thereof
    Patent number: 8338452
    Abstract: Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: December 25, 2012
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: Kateri A. Ahrendt, Alexandre J. Buckmelter, Jonas Grina, Joshua D. Hansen, Ellen R. Laird, David Moreno, Brad Newhouse, Li Ren, Steven M. Wenglowsky, Bainian Feng, Janet Gunzner, Kim Malesky, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Wendy B. Young
  • 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors
    Patent number: 8329709
    Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: December 11, 2012
    Assignees: Genentech, Inc., Array BioPharma Inc.
    Inventors: Anna L. Banka, Josef R. Bencsik, James Blake, Martin Hentemann, Nicholas C. Kallan, Jun Liang, Ian S. Mitchell, Stephen T. Schlachter, Eli M. Wallace, Rui Xu, Tony P. Tang
  • Dihydrofuro pyrimidines as AKT protein kinase inhibitors
    Patent number: 8329701
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: December 11, 2012
    Assignee: Array Biopharma Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik
  • Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
    Patent number: 8324221
    Abstract: The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: December 4, 2012
    Assignee: Array Biopharma Inc.
    Inventors: Anna L. Banka, James F. Blake, Josef R. Bencsik, Kin Chiu Fong, Martin F. Hentemann, Douglas M. Sammond, Ian S. Mitchell, Rui Xu, Eli M. Wallace, Tony Tang
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 8324257
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: December 4, 2012
    Assignee: Array Biopharma Inc.
    Inventors: Kateri Ahrendt, Robert Kirk Delisle, Jeremy Hans, Joseph P. Lyssikatos, John E. Robinson, Eli M. Wallace, Qian Zhao
  • Methods of synthesis of benzazepine derivatives
    Patent number: 8314090
    Abstract: The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: November 20, 2012
    Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: J. Jeffry Howbert, Venkat Reddy Kusukuntla, Alexander Tretyakov, Nathan Nielsen, Pavel Krasik, Ji-Long Jiang, Hong Woon Yang
  • 8-substituted benzoazepines as toll-like receptor modulators
    Patent number: 8304407
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: November 6, 2012
    Assignee: Array BioPharma Inc.
    Inventors: George A. Doherty, Charles Todd Eary, Robert D. Groneberg, Zachary Jones
  • Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
    Patent number: 8299076
    Abstract: Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: October 30, 2012
    Assignees: Array Biopharma Inc., Astrazeneca AB
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, Jim Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 8278314
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: October 2, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 8268871
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: September 18, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Shelley Allen, Ellen Laird, Joseph P. Lyssikatos, John E. Robinson, Christopher P. Corrette, Robert Kirk DeLisle, Walter C. Voegtli
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 8268852
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: September 18, 2012
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Joseph P. Lyssikatos, Hong-Woon Yang, Eli M. Wallace, Jeongbeob Seo
  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20120232055
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: October 12, 2011
    Publication date: September 13, 2012
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: Ian S. MITCHELL, James F. BLAKE, Rui XU, Nicholas C. KALLAN, Dengming XIAO, Keith Lee SPENCER, Josef R. BENCSIK, Eli M. WALLACE, Stephen T. SCHLACHTER, Anna L. BANKA, Jun LIANG, Brian SAFINA, Birong ZHANG, Christine CHABOT, Steven DO